This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Amarin (AMRN) Q3 Earnings Top, Vascepa Sales Decline Y/Y
by Zacks Equity Research
Amarin's (AMRN) reports lower sales volume for its drug, Vascepa, in the United States during the third quarter. The company's stock falls in pre-market trading.
Dr. Reddy's (RDY) Q2 Earnings, Sales Increase Year Over Year
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2022.
Citius (CTXR) Acquires Dr. Reddy's License for NHL Therapy
by Zacks Equity Research
Citius Pharmaceuticals (CTXR) acquires Dr. Reddy's exclusive license rights for E7777 to treat a rare form of NHL and other cancer indications.
BioMarin (BMRN) Phenylketonuria Gene Therapy on Clinical Hold
by Zacks Equity Research
BioMarin's (BMRN) phase I/II study on gene therapy candidate, BMN 307, has been placed under a clinical hold by the FDA possibly on malignancy concerns.
3 Generic Drug Stocks to Watch Amid Pandemic & Pricing Pressure
by Zacks Equity Research
The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in the second half of 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.
Amarin (AMRN) Q2 Earnings Top, Vascepa Strong Despite Generics
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales benefit from increased demand in the United States during the second quarter. The drug retains majority market share in its segment amid rising generic competition. Stock up.
Dr. Reddy's (RDY) Q1 Earnings Decline Y/Y, Sales Increase
by Zacks Equity Research
Dr. Reddy's (RDY) earnings decline while sales grow year over year in first-quarter fiscal 2022.
Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase
by Zacks Equity Research
Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2021.
Amarin (AMRN) Q1 Earnings Top, Vascepa Sales Hit by COVID-19
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales get hit by COVID-19 and by severe winter storms and power outages in various areas of the United States. Its cost management plan boost the bottom line. Stock up.
3 Generic Drug Stocks to Watch Amid COVID-Related Recovery
by Indrajit Bandyopadhyay
The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.
Amarin (AMRN) Q4 Earnings & Revenues Top, Vascepa Sales Solid
by Zacks Equity Research
Amarin's (AMRN) revenue growth in the fourth quarter is attributable to continued demand for its cardiovascular drug, Vascepa.
Dr. Reddy's (RDY) Q3 Earnings Decline Y/Y, Sales Increase
by Zacks Equity Research
Dr. Reddy's (RDY) earnings decline while sales grow year over year in third-quarter fiscal 2021.
Dr. Reddy's (RDY) Ends Kuwait Study on Avigan for COVID-19
by Zacks Equity Research
Dr. Reddy's (RDY) and Global Response Aid FZCO terminate the Avigan study conducted in Kuwait, focused on moderate-to-severe COVID patients in a hospital setting.
Dr. Reddy's (RDY) to Begin Phase III Study on Sputnik Vaccine
by Zacks Equity Research
Dr. Reddy's (RDY) receives approval from the DCGI to conduct a phase III study on the Sputnik V vaccine for the treatment of COVID-19 in India.
Exelixis (EXEL) Reports Preliminary Q4 Results, Business Updates
by Zacks Equity Research
Exelixis (EXEL) provides preliminary results for the fourth quarter and 2020 along with the annual guidance for 2021. It also throws light on anticipated milestones for 2021.
The Zacks Analyst Blog Highlights: Brilliance China, Baidu, Impala and Dr. Reddy's
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Brilliance China, Baidu, Impala and Dr. Reddy's
4 Emerging Market Stocks to Tap 2021 Economic Rebound
by Urmimala Biswas
Here we discuss four emerging market stocks, BCAUY, BIDU, IMPUY and RDY, which have solid growth prospects for 2021.
Exelixis (EXEL) In-Licenses Aurigene's Compound, Files IND
by Zacks Equity Research
Exelixis (EXEL) exercises an option to in-license Aurigene's novel CDK7 inhibitor and submits an IND to the FDA for evaluating the candidate in a phase I study.
3 Generic Drug Stocks to Watch Amid COVID-Induced Uncertainty
by Zacks Equity Research
The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is difficult to gauge. However, stable pricing and improvement in demand in some countries in 2021 may bode well for RDY, BHC and VTRS.
Amarin's (AMRN) Q3 Earnings Lag, Sales In Line, Stock Down
by Zacks Equity Research
Amarin's (AMRN) revenue growth in the third quarter is attributable to continued demand for its cardiovascular drug, Vascepa. Generic competition for Vascepa seems imminent.
Endo (ENDP) Q3 Earnings & Sales Top Estimates, View Raised
by Zacks Equity Research
Endo's (ENDP) earnings and sales beat estimates in the third quarter. The company raises its annual outlook.
Bausch's (BHC) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Bausch (BHC) reports better-than-expected results for the third quarter as the business shows recovery signs from the COVID-19 pandemic.
Dr. Reddy's (RDY) Q2 Earnings Decline Y/Y, Sales Increase
by Zacks Equity Research
Dr. Reddy's (RDY) earnings decline year over year while sales increase in second-quarter fiscal 2021.
Bausch Acquires License for Myopia Solution from Eyenovia
by Zacks Equity Research
Bausch (BHC) acquires license for an investigational microdose formulation of atropine ophthalmic solution from Eyenovia.
BioMarin (BMRN) Gets FDA Approval for Higher Dose of Palynziq
by Zacks Equity Research
The FDA approves higher dose (60 mg) of BioMarin's (BMRN) Phenylketonuria drug Palynziq injection. The regulatory nod includes the addition of longer-term efficacy data on Palynziq's label.